Copyright
©The Author(s) 2017.
World J Radiol. May 28, 2017; 9(5): 245-252
Published online May 28, 2017. doi: 10.4329/wjr.v9.i5.245
Published online May 28, 2017. doi: 10.4329/wjr.v9.i5.245
Table 1 Demographic characteristics and tumoral parameters of the study population, n (%)
| Age (yr) | 67 (49-95) |
| Sex | |
| Male | 42 (87.5) |
| Female | 6 (13.5) |
| Aetiology | |
| HCV | 27 (56.2) |
| HBV | 9 (18.75) |
| Alcohol | 6 (12.5) |
| Cryptogenetic | 3 (6.25) |
| NASH | 3 (6.25) |
| Child-Pugh | |
| A | 45 (93.4) |
| B | 3 (6.6) |
| MELD | 8 (6-14) |
| BCLC | |
| A | 21 (43.8) |
| B | 27 (56.2) |
| ECOG 0 | 48 (100) |
| Portal hypertension | |
| Yes | 22 (45.9) |
| No | 26 (54.1) |
| Tumour extension | |
| Unilobar | 29 (60.4) |
| Bilobar | 19 (39.6) |
| No. of tumors (target) | |
| Total | 128 |
| Median | 2 (1-4) |
| Max. diameter (mm) | 30 (10-96) |
| Sum of diameters (mm) | 44 (13-130) |
| TACE | |
| Total cycles | 73 |
| Segmental | 47 (64.4) |
| Bisegmental | 22 (30.1) |
| Trisegmental | 4 (5.5) |
Table 2 Target lesions: Modified Response Evaluation Criteria in Solid Tumors response rate
| Ø nodules | No. of nodules | CR | PR | SD | PD |
| Ø < 3 cm | 77 | 47.4% | 21.6% | 27.8% | 3.2% |
| 3 ≤ Ø ≤ 5 cm | 22 | 42.8% | 42.8% | 10.8% | 3.6% |
| Ø > 5 cm | 3 | 40% | 30% | 30% | 0% |
| Overall response | 102 | 46% | 26.6% | 24.4% | 3% |
Table 3 Target lesions: Response Evaluation Criteria in Solid Tumors response rate
| Ø nodules | No. of nodules | CR | PR | SD | PD |
| Ø < 3 cm | 77 | 6.2% | 20.6% | 66% | 7.2% |
| 3 ≤ Ø ≤ 5 cm | 22 | 3.5% | 28.6% | 64.4% | 3.5% |
| Ø > 5 cm | 3 | 0% | 10% | 90% | 0% |
| Overall response | 102 | 5.2% | 21.5% | 67.4% | 5.9% |
Table 4 Histological response rate of treated nodules in patients submitted to orthotopic transplantation
| Ø nodules | Degree of necrosis | ||
| 100% | > 90% | < 50% | |
| Ø < 3 cm | 7 | - | 3 |
| 3 ≤ Ø ≤ 5 cm | 2 | 2 | - |
| Overall necrosis | 9 (64.3%) | 2 (14.3%) | 3 (21.4%) |
Table 5 Adverse events
| Toxicity | Grade 1/2 | Grade 3/4 |
| Clinical findings | ||
| Post embolization syndrome | 11/73 (15%) | - |
| Ascites | 3/73 (4.1%) | - |
| Abdominal pain | 18/73 (24.6%) | - |
| Nausea/vomiting | 9/73 (12.3%) | - |
| Laboratory tests | ||
| Bilirubin | 5/73 (6.8%) | - |
| Transaminase | 10/73 (13.7%) | - |
- Citation: Greco G, Cascella T, Facciorusso A, Nani R, Lanocita R, Morosi C, Vaiani M, Calareso G, Greco FG, Ragnanese A, Bongini MA, Marchianò AV, Mazzaferro V, Spreafico C. Transarterial chemoembolization using 40 µm drug eluting beads for hepatocellular carcinoma. World J Radiol 2017; 9(5): 245-252
- URL: https://www.wjgnet.com/1949-8470/full/v9/i5/245.htm
- DOI: https://dx.doi.org/10.4329/wjr.v9.i5.245